Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Double spread collar in Amarin(AMRN) opens bullish position.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
zumantu Member Profile
 
Followed By 39
Posts 5,708
Boards Moderated 0
Alias Born 02/25/11
160x600 placeholder
Amarin Supports Investigator-Initiated Trial at Kaiser Permanente in the U.S. to Study the Effects of VASCEPA® (icosapent et... GlobeNewswire Inc. - 8/7/2020 12:12:27 PM
Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe GlobeNewswire Inc. - 8/4/2020 6:30:26 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/4/2020 6:17:36 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 6:11:39 AM
Amarin Reports Second Quarter 2020 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 8/4/2020 6:00:10 AM
VASCEPA® (icosapent ethyl) Data from REDUCE-IT® REVASC, Including New Data on Timeframe to Demonstrated Benefit, Presented ... GlobeNewswire Inc. - 7/27/2020 7:00:10 AM
Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020 GlobeNewswire Inc. - 7/21/2020 4:15:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/14/2020 5:20:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/16/2020 5:29:34 PM
Amarin Announces Patent Litigation Settlement Agreement with Apotex Inc. GlobeNewswire Inc. - 6/16/2020 4:30:10 PM
VASCEPA® (icosapent ethyl) Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified and Post ... GlobeNewswire Inc. - 6/15/2020 7:00:10 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 6/1/2020 4:15:58 PM
Amarin Plans to Increase VASCEPA® (icosapent ethyl) Promotion and Education GlobeNewswire Inc. - 6/1/2020 7:00:10 AM
Amarin Supports Trial to Investigate the Effects of VASCEPA® (icosapent ethyl) in the Treatment of COVID-19 GlobeNewswire Inc. - 5/21/2020 4:05:10 PM
VASCEPA® (icosapent ethyl) Shows Significant Reduction in Coronary Revascularization, Including Coronary Stenting and Cardia... GlobeNewswire Inc. - 5/14/2020 2:50:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2020 5:19:58 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/30/2020 6:39:17 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/30/2020 6:32:26 AM
Amarin Reports First Quarter 2020 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 4/30/2020 5:00:10 AM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/29/2020 4:12:49 PM
Amarin to Report First Quarter 2020 Results and Host Conference Call on April 30, 2020 GlobeNewswire Inc. - 4/28/2020 7:00:10 AM
Cannabis? CBD? That's Old News, A New Sector Bull Run Has Begun InvestorsHub NewsWire - 4/16/2020 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/13/2020 4:37:32 PM
Amarin to Host Conference Call on April 13, 2020 to Provide Preliminary First Quarter 2020 Results and Operational Update GlobeNewswire Inc. - 4/8/2020 4:05:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/31/2020 9:23:01 AM
zumantu   Monday, 06/22/20 12:05:09 PM
Re: None
Post # of 290435 
Double spread collar in Amarin(AMRN) opens bullish position. Shares little changed this morning near $6.80 with a 4-way spread on the ISE where a customer appears to have sold the Sep 5/6 put spread to buy the Sep 7/10 call spread a total of 20k times, opening on all legs. For the largest tranche of 15k, the net credit on the put spread was 27c and the debit on the call spread 77c, for a net debit of 50c, or about $1M on the package. Net delta on the package is nearly 670k shares, or 9% the average daily turnover in the name. Amarin(AMRN) shares dropped nearly 70% from over $13 to $4 on March 31 related to a court ruling. Today's trade could return a 500% gain to the buyer if shares were to return to double digit territory over the next three months.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist